Courtney Flaherty

SNB-101 has received FDA fast track designation for potential use in patients with small cell lung cancer.

Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.

Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.

The CAR T-cell therapy NXC-201 has received orphan drug designation from the European Commission for patients with multiple myeloma.

Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.

Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.

Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.

Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.

Olutasidenib alone or administered with azacitidine was safe and clinically effective in patients with IDH1-mutated myelodysplastic syndrome.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.

The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.

Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.

Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.

LSTA1 has been granted orphan drug designation by the FDA for the treatment of patients with osteosarcoma.

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.

Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.